RxDoctor Payments Data

Giorgio Roccaro, MD

Transplant Hepatology · Atlanta, GANPI 1205121985

Payments from drug & device makers

$12,869in general payments, 2019–2025

Across 20 payments — averaging $643.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fujifilm Healthcare Americas Corporation$7K
  • Biomarin Pharmaceutical Inc.$2K
  • Transmedics, Inc.$2K
  • Gilead$296
  • Boston Scientific$164
  • Madrigal Pharmaceuticals$112
  • plus $128 from 2 others

What the payments were for

  • Consulting fees$2,40019%
  • Speaking & faculty fees$6,86853%
  • Travel & lodging$2,33218%
  • Food & beverage$1,26910%

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant hepatology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$31,593
Medicare patients
173
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin46$147,636
VemlidyTenofovir Alafenamide88$146,872
RezdiffraResmetirom17$65,254
Tacrolimus242$47,214
Ursodiol105$16,164
Mycophenolate Mofetil87$9,731
Entecavir29$7,651
Atovaquone21$7,455
Cyclosporine ModifiedCyclosporine, Modified36$4,777
Nifedipine ErNifedipine84$2,601
Pantoprazole Sodium157$1,326
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,106
Azathioprine26$888
Carvedilol125$862
Spironolactone74$835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$296$146,87288 claims
Madrigal PharmaceuticalsRezdiffra$112$65,25417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few transplant hepatology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other transplant hepatology in Atlanta

Where these figures come from

Is this you, or does something look wrong? →